Preexisting AICs and their treatment history before the start of treatment with a targeted drug
| . | Ibrutinib n/N (%) . | Idelalisib n/N (%) . | Venetoclax n/N (%) . |
|---|---|---|---|
| Total preexisting AICs | 66/572 (12) | 29/143 (20) | 9/100 (9) |
| AIHA | 38/66 (58) | 16/29 (55) | 5/9 (56) |
| ITP | 18/66 (27) | 8/29 (28) | 2/9 (22) |
| PRCA | 1/66 (1) | ||
| AIHA + ITP | 9/66 (14) | 5/29 (17) | 2/9 (22) |
| Previous treatments for AIC | |||
| Total | 63/66 (95) | 29/29 (100) | 9/9 (100) |
| Steroids only | 31/63 (49) | 12/29 (42) | 7/9 (78) |
| IVIG ± steroids | 3/63 (5) | 3/29 (11) | |
| Rituximab ± steroids | 4/29 (14) | 2/9 (22) | |
| Rituximab ± IVIG ± steroids | 12/63 (19) | ||
| Thrombopoietin mimetics + steroids | 1/29 (3) | ||
| Thrombopoietin mimetics + steroids + IVIG + rituximab | 1/63 (2) | ||
| Cyclosporine | 1/63 (2) | ||
| Cyclosporine + steroids | 1/29 (3) | ||
| Chemotherapy + steroids ± rituximab ± IVIG | 6/29 (21) | ||
| Chemotherapy ± steroids ± rituximab ± IVIG | 9/63 (14) | ||
| Splenectomy | 1/29 (3) | ||
| Splenectomy ± steroids | 2/63 (3) | ||
| Splenectomy + steroids + IVIG ± rituximab ± chemotherapy | 2/63 (3) | ||
| Other | 2/63 (3) | 1/29 (3) |
| . | Ibrutinib n/N (%) . | Idelalisib n/N (%) . | Venetoclax n/N (%) . |
|---|---|---|---|
| Total preexisting AICs | 66/572 (12) | 29/143 (20) | 9/100 (9) |
| AIHA | 38/66 (58) | 16/29 (55) | 5/9 (56) |
| ITP | 18/66 (27) | 8/29 (28) | 2/9 (22) |
| PRCA | 1/66 (1) | ||
| AIHA + ITP | 9/66 (14) | 5/29 (17) | 2/9 (22) |
| Previous treatments for AIC | |||
| Total | 63/66 (95) | 29/29 (100) | 9/9 (100) |
| Steroids only | 31/63 (49) | 12/29 (42) | 7/9 (78) |
| IVIG ± steroids | 3/63 (5) | 3/29 (11) | |
| Rituximab ± steroids | 4/29 (14) | 2/9 (22) | |
| Rituximab ± IVIG ± steroids | 12/63 (19) | ||
| Thrombopoietin mimetics + steroids | 1/29 (3) | ||
| Thrombopoietin mimetics + steroids + IVIG + rituximab | 1/63 (2) | ||
| Cyclosporine | 1/63 (2) | ||
| Cyclosporine + steroids | 1/29 (3) | ||
| Chemotherapy + steroids ± rituximab ± IVIG | 6/29 (21) | ||
| Chemotherapy ± steroids ± rituximab ± IVIG | 9/63 (14) | ||
| Splenectomy | 1/29 (3) | ||
| Splenectomy ± steroids | 2/63 (3) | ||
| Splenectomy + steroids + IVIG ± rituximab ± chemotherapy | 2/63 (3) | ||
| Other | 2/63 (3) | 1/29 (3) |
±, Indicates with or without a drug.
IVIG, intravenous immunoglobulin; PRCA, pure red cell aplasia.